Rho kinase inhibitors: A patent review (2012-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 3, 2014, Pages 295-307

  Feng, Yangbo ^a   Lograsso, Philip V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Bis functional inhibitor; Isoform selectivity; Kinase inhibitor; Reverse pro drug; Rho kinase; ROCK; ROCK inhibitor; Soft drug

Indexed keywords

FASUDIL; MOLECULAR SCAFFOLD; RHO KINASE INHIBITOR;

BIOLOGICAL FUNCTIONS; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG RESEARCH; HUMAN; PATENT; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896726589     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.863279     Document Type: Review

References (132)

1. Sun X, Minohara M, Kikuchi H, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006;180:126-34
2. Zhou Q, Liao JK. Rho kinase: An important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009;15:3108-15
3. Gu H, Yu SP, Gutekunst CA, et al. Inhibition of the Rho signaling pathway improves neurite outgrowth and neuronal differentiation of mouse neural stem cells. Int J Physiol Pathophysiol Pharm 2013;5:11-20
4. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98
5. Hu E, Lee D. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Curr Opin Investig Drugs 2003;4:1065-75
6. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007;50:17-24
7. Arnold JJ, Hansen MS, Gorman GS, et al. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. Invest Ophthalmol Vis Sci 2013;54:1118-26
8. Inoue T, Tanihara H. Rho-associated kinase inhibitors: A novel glaucoma therapy. Prog Retin Eye Res 2013
9. Watabe H, Abe S, Yoshitomi T. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries. Jpn J Ophthalmol 2011;55:411-17
10. Alt A, Hilgers RD, Tura A, et al. The neuroprotective potential of rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in response to hypoxia in isolated bovine retina. Cell Physiol Biochem 2013;32:218-34
11. Fang X, Ueno M, Yamashita T, et al. RhoA activation and effect of Rho-kinase inhibitor in the development of retinal neovascularization in a mouse model of oxygen-induced retinopathy. Curr Eye Res 2011;36:1028-36
12. Hata T, Goto C, Soga J, et al. Measurement of Rho-associated kinase (ROCK) activity in humans: Validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis 2011;214:117-21
13. Zhou H, Li YJ. Rho kinase inhibitors: Potential treatments for diabetes and diabetic complications. Curr Pharm Des 2012;18:2964-73
14. Isgro J, Gupta S, Jacek E, et al. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:1592-602
15. Stirzaker RA, Biswas PS, Gupta S, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupusprone NZB/W F1 female mice. Lupus 2012;21:656-61
16. Kubo T, Hata K, Yamaguchi A, et al. Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. Curr Pharm Des 2007;13:2493-9
17. Yu JZ, Ding J, Ma CG, et al. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J Neurosci Res 2010;88:1664-72
18. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005;36:2251-7
19. Liu C, Zuo J, Pertens E, et al. Regulation of Rho/ROCK signaling in airway smooth muscle by membrane potential and [Ca2+]i. Am J Physiol Lung Cell Mol Physiol 2005;289:L574-82
20. Nakahara T, Moriuchi H, Yunoki M, et al. Y-27632 potentiates relaxant effects of beta 2-adrenoceptor agonists in bovine tracheal smooth muscle. Eur J Pharmacol 2000;389:103-6
21. Gerthoffer WT, Solway J, Camoretti-Mercado B. Emerging targets for novel therapy of asthma. Curr Opin Pharmacol 2013;13:324-30
22. Schaafsma D, Gosens R, Zaagsma J, et al. Rho kinase inhibitors: A novel therapeutical intervention in asthma Eur J Pharmacol 2008;585:398-406
23. Hallgren O, Rolandsson S, Andersson-Sjoland A, et al. Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients. J Transl Med 2012;10:171
24. Guo R, Liu B, Zhou S, et al. The protective effect of fasudil on the structure and function of cardiac mitochondria from rats with type 2 diabetes induced by streptozotocin with a high-fat diet is mediated by the attenuation of oxidative stress. BioMed Res Int 2013;2013:430791
25. Horton JW, Maass DL, Ballard-Croft C. Rho-associated kinase modulates myocardial inflammatory cytokine responses. Shock 2005;24:53-8
26. Kushiyama T, Oda T, Yamamoto K, et al. Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease. Am J Physiol Renal Physiol 2013;304:F1325-34
27. Hannan JL, Albersen M, Kutlu O, et al. Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol 2013;189:1155-61
28. Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008;57:714-23
29. Sagawa H, Terasaki H, Nakamura M, et al. A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol 2007;205:230-40
30. Ichikawa M, Yoshida J, Saito K, et al. Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats. Brain Res 2008;27:23-33
31. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, et al. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinsons disease. Neurobiol Dis 2013;58:209-19
32. Tonges L, Frank T, Tatenhorst L, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinsons disease. Brain 2012;135:3355-70
33. Ohsawa M, Aasato M, Hayashi SS, et al. RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011;152:114-22
34. Takeshita N, Yoshimi E, Hatori C, et al. Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents. J Pharmacol Sci 2011;115:481-9
35. Nakajima M, Hayashi K, Egi Y, et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 2003;52:319-24
36. Liu CM, Fan YC, Lo YC, et al. Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia. Int J Urol 2013. DOI:10.1111/iju.12195
37. Saito M, Ohmasa F, Shomori K, et al. Rhos and Rho kinases in the rat prostate: Their possible functional roles and distributions. Mol Cell Biochem 2011;358:207-13
38. Street CA, Routhier AA, Spencer C, et al. Pharmacological inhibition of Rhokinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol 2010;37:1297-305
39. Deng L, Li G, Li R, et al. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 2010;9:875-84
40. Erkutlu I, Cigiloglu A, Kalender ME, et al. Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme. Tumour Boil 2013;34:1139-44
41. Biswas PS, Gupta S, Chang E, et al. Aberrant ROCK activation promotes the development of type I diabetes in NOD mice. Cell Immunol 2011;266:111-15
42. Kanazawa Y, Takahashi-Fujigasaki J, Ishizawa S, et al. The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells. Exp Neurol 2013;247:438-46
43. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective rock inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;126:309-15
44. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137-44
45. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007;48:3216-22
46. Waki M, Yoshida Y, Oka T, et al. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-4
47. Ishikawa H, Yoshitomi T, Mashimo K, et al. Pharmacological effects of latanoprost, prostaglandin E2, and F2alpha on isolated rabbit ciliary artery. Graefes Arch Clin Exp Ophthalmol 2002;240:120-5
48. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study. J Cardiovasc Pharmacol 2002;40:751-61
49. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-11
50. Shibuya M, Hirai S, Seto M, et al. Effects of fasudil in acute ischemic stroke: Results of a prospective placebocontrolled double-blind trial. J Neurol Sci 2005;238:31-9
51. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-7
52. Khan MO, Park KK, Lee HJ. Antedrugs: An approach to safer drugs. Curr Med Chem 2005;12:2227-39
53. Shimizu K, Kawase A, Haneishi T, et al. Novel vitamin D3 antipsoriatic antedrugs: 16-En-22-oxa-1alpha,25-(OH) 2D3 analogs. Bioorg Med Chem 2006;14:1838-50
54. Leysen D, Defert O, Boland S, et al. Novel ROCK inhibitors. WO2012146724; 2012.. A patent application from Amakem describing the rationale and methods for making soft Rho kinase (ROCK) inhibitors.
55. Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of rho kinase inhibitors. Bioorg Med Chem 2007;15:350-67
56. Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of rho kinase inhibitors (III). Bioorg Med Chem 2007;15:1022-33
57. Takami A, Iwakubo M, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (I). Bioorg Med Chem 2004;12:2115-37. References [55-57] are the three classical papers describing the development of ROCK inhibitors based on fragment-and structureguided designs.
58. Schroter T, Griffin E, Weiser A, et al. Detection of myosin light chain phosphorylation-A cell-based assay for screening Rho-kinase inhibitors. Biochem Biophys Res Commun 2008;374:356-60
59. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective rock inhibitor SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;128:309-15
60. Waki M, Yoshida Y, Oka T, et al. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-4
61. Ishizaki T, Naito M. Fujisawa K, et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 1997;404:118-24
62. Nakajima M, Hayashi K, Katayama K, et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 2003;459:113-20
63. Leysen D, Defert O, Boland S. Novel soft rock inhibitors. WO2013030216; 2013.. A patent application from Amakem describing the rationale and methods for making soft ROCK inhibitors.
64. Leysen D, Defert O, Kaval N, et al. Heterocyclic amides as rock inhibitors. WO2011107608; 2011.. A patent application from Amakem describing the rationale and methods for making soft ROCK inhibitors.
65. Boland S, Defert O, Alen J, et al. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl) carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg Med Chem Lett 2013;23:6442-6.. This is the first journal publication describing soft ROCK inhibitors.
66. Allen J, Boland S, Bourin A, et al. Novel ROCK inhibitors. WO2013030365; 2013.. A patent application from Amakem describing the rationale and methods for making soft ROCK inhibitors.
67. Allen J, Boland S, Bourin A, et al. Novel soft ROCK inhibitors. WO2013030366; 2013.. A patent application from Amakem describing the rationale and methods for making soft ROCK inhibitors.
68. Allen J, Boland S, Bourin A, et al. Biphenylcarboxamides As ROCK kinase inhibitors. WO2013030367; 2013.. A patent application from Amakem describing the rationale and methods for making soft ROCK inhibitors.
69. Schonbrunn E, Li R, Sebti SM. Inhibitors of rho associated protein kinases (rock) and methods of use. WO2013112722; 2013
70. Li R, Martin MP, Liu Y, et al. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem 2012;55:2474-8.. Use of NMR technique for fragment based design of ROCK inhibitors.
71. Patel RA, Liu Y, Wang B, et al. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 2013; [Epub ahead of print]
72. Feng Y, Cameron MD, Frackowiak B, et al. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. Bioorg Med Chem Lett 2007;17:2355-60
73. Chen YT, Bannister TD, Weiser A, et al. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg Med Chem Lett 2008;18:6406-9
74. Chowdhury S, Chen YT, Fang X, et al. Amino acid derived quinazolines as rock/PKA inhibitors. Bioorg Med Chem Lett 2013;23:1592-9
75. Fang X, Yin Y, Chen YT, et al. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem 2010;53:5727-37
76. Feng Y, Yin Y, Weiser A, et al. Discovery of substituted 4-(Pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem 2008;51:6640-5. Describing the first pyrazole based ROCK inhibitor.
77. Yin Y, Lin L, Ruiz C, et al. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. J Med Chem 2013;56:3568-81
78. Nakajima M, Katayama K, Tamechika I, et al. WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin Exp Pharmacol Physiol 2003;30:457-63
79. Yada T, Shimokawa H, Hiramatsu O, et al. Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol 2005;45:599-607
80. Yamada R, Seto M. 5-Substituted isoquinoline derivative. WO2004009555; 2004
81. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241:1033-40
82. Iwakubo M, Okada Y, Yoshitake K. Isoquinoline derivatives having kinase inhibitory activity and drugs containing the same. WO2004024717; 2004
83. Drewry D, Evans B, Goodman K, et al. Chemical compounds. WO2004112719; 2004
84. Goodman KB, Cui H, Dowdell SE, et al. Development of dihydropyridone indazole amides as selective rho-kinase inhibitors. J Med Chem 2007;50:6-9
85. Stavenger RA, Cui H, Dowdell SE, et al. Discovery of aminofurazanazabenzimidazoles as inhibitors of Rhokinase with high kinase selectivity and antihypertensive activity. J Med Chem 2007;50:2-5
86. Doe C, Bentley R, Behm DJ, et al. Novel Rho kinase inhibitors with antiinflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007;320:89-98
87. Drewry D, Jung D, Linn J, et al. Chemical Compounds. WO2005074643; 2005
88. Sessions EH, Yin Y, Bannister TD, et al. Benzimidazole and benzoxazole based inhibitors of Rho kinase. Bioorg Med Chem Lett 2008;18:6390-6
89. Davis RL, Kahraman M, Prins TJ, et al. Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma. Bioorg Med Chem Lett 2010;20:3361-6
90. Chowdhury S, Sessions EH, Pocas JR, et al. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). Bioorg Med Chem Lett 2011;21:7107-12
91. Fang X, Chen YT, Sessions EH, et al. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors. Bioorg Med Chem Lett 2011;2:1844-8
92. Sessions EH, Chowdhury S, Yin Y, et al. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II). Bioorg Med Chem Lett 2011;21:7113-18
93. Sessions EH, Smolinski M, Wang B, et al. The Development of Benzimidazoles as Selective Rho Kinase Inhibitors. Bioorg Med Chem Lett 2010;20:1039-43
94. Yin Y, Cameron MD, Lin L, et al. Discovery of highly potent and selective urea-based rockinhibitors and their effects on intraocular pressure in rats. ACS Med Chem Lett 2010;1:175-9
95. Yin Y, Lin L, Ruiz C, et al. Benzothiazole as Rho-associated Kinase (ROCK-II) Inhibitors. Bioorg Med Chem Lett 2009;19:6686-90
96. Cook BN, Kowalski J, Li X, et al. NCyclyl-3-(Cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors. WO2012006203; 2012. Novel ROCK inhibitors based on benzamides and without apparent hinge binding moiety.
97. HOU T, YU H, Shen M, et al. Application of 3-4-(sulfonyl)benzene] urea compound to preparation of antitumor medicament. CN102327275, 2012
98. HOU T, YU H, Shen M, et al. 4,7-dihydrotetrazole[1,5-a]pyrimidine derivative and application thereof to preparation of antitumor medicine. CN102432612; 2012. Describing an interesting scaffold for ROCK inhibitors having interactions in hydrophobic pocket-I.
99. Hou T, YU H, Shen M, et al. Application of compound in preparing anti-tumor medicament. CN102697782; 2012
100. Curtin ML, Sorensen BK, Heyman HR, et al. NAMPT and ROCK inhibitors. WO2012067965; 2012.. Describing an interesting scaffold having inhibition to both ROCK and NAMPT.
101. Van Beijnum JR, Moerkerk PT, Gerbers AJ, et al. Target validation for genomics using peptide-specific phage antibodies: A study of five gene products overexpressed in colorectal cancer. Int J Cancer 2002;101:118-27
102. Adya R, Tan BK, Chen J, et al. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: Its role in MMP-2/9 production and activation. Diabetes Care 2008;31:758-60
103. Lampe JW, Watson PS, Vittitow JL, et al. Bifunctional rho kinase inhibitor compounds composition and use. WO2012012282; 2012.. Describing the design and preparation of bis-functional inhibitors with ROCK inhibition moiety and a prostaglandin derivative.
104. Lampe JW, Watson PS, Vittitow JL, et al. Bifunctional rho kinase inhibitor compounds composition and use. US20130131106; 2013
105. Wang L, Xue L, Yan H, et al. Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep 2010;37:1971-7
106. Yin L, Morishige K, Takahashi T, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007;6:1517-25
107. Ying H, Biroc SL, Li WW, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006;5:2158-64
108. Belgiovine C, Frapolli R, Bonezzi K, et al. Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. PLoS One 2010;5:e14154
109. Takamura M, Sakamoto M, Genda T, et al. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001;33:577-81
110. Kapur R. Rho kinase inhibitors for treatment of mastocytosis and acute myeloid leukemia. US20130046009; 2013. Anti-proliferation applications of known ROCK inhibitors.
111. Lingor P, Teusch N, Schwarz K, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 2007;103:181-9
112. Harvey KA, Paranavitana CN, Zaloga GP, et al. Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation. J Cell Physiol 2007;211:353-63
113. Versteeg R, Koster JJ.B, Molenaar JJ, et al. Rho kinase inhibitors for use in the treatment of neuroblastoma. EP2628482; 2013. Anti-proliferation application of classical ROCK inhibitors for treatment of brain cancers.
114. Schultz A, Larsson C. Ceramide influences neurite outgrowth and neuroblastoma cell apoptosis regulated by novel protein kinase C isoforms. J Neurochem 2004;89:1427-35
115. Shin HK, Salomone S, Potts EM, et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2007;27:998-1009
116. Yamashita K, Kotani Y, Nakajima Y, et al. Fasudil a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007;1154:215-24
117. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 Randomized clinical study of a rho kinase inhibitor k-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2013;56:731-6
118. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-7
119. Grisk O, Schluter T, Reimer N, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens 2012;30:980-9
120. Kast R, Schirok H, Figueroa-Perez S, et al. Cardiovascular effects of a novel potent and highly selective azaindolebased inhibitor of Rho-kinase. Br J Pharmacol 2007;152:1070-80
121. Williams J, Bogwu J, Oyekan A. The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice. J Hypertens 2006;24:1429-36
122. Stavenger R. In Gordon Conference on Medicinal Chemistry; 2007.. Detailed data describing the hypertension effects of ROCK inhibitors based on several scaffolds.
123. Krejbich-Trotot P, Denizot M, Hoarau JJ, et al. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J 2011;25:314-25
124. Lei S, Tian YP, Xiao WD, et al. ROCK is involved in vimentin phosphorylation and rearrangement induced by dengue virus. Cell Biochem Biophys 2013, DOI:10.1007/s12013-013-9665-x
125. Vorster PJ, Guo J, Yoder A, et al. LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection. J Biol Chem 2011;286:12554-64
126. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: A patent review 2007-2011. Expert Opin Ther Patents 2012;22:79-88
127. Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS 1998;2:43-7
128. Baudouin C. Liang H. [Vaccine for glaucoma, myth or reality]. J Fr Ophtalmol 2006;29(2):9-12
129. Herskowitz JH, Feng Y, Higginbotham L, et al. Pharmacologic inhibition of ROCK2 reduces BACE1 activity and amyloid-b production in an Alzheimer disease mouse model. J Neurosci 2013; DOI:10.1523/JNEUROSCI.2508-13.2013.. The first research report describing the different effects of ROCK1 and ROCK2 inhibitions on the reduction of Ab level in vitro and in vivo.
130. Campbell S, Foudoulakis H, Kirk B, et al. Pharmacokinetically improved compounds. WO2006105081; 2006.. The only publication showing compounds with significant isoform selectivity of ROCK2 over ROCK1.
131. Takeshita N. Pain remedy containing ROCK inhibitor. EP1854484, 2007
132. Yoshimi E, Kumakura F, Hatori C, et al. Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. J Pharmacol Exp Ther 2010;334:955-63